A Modular Biomaterial Scaffold-Based Vaccine Elicits Durable Adaptive Immunity to Subunit SARS-CoV-2 Antigens.

"Conflict of Interest Several authors are inventors on patent applications related to this technology (E.D, D.J.M); Novartis, sponsored research (D.J.M); Immulus, equity (D.J.M.), Attivare Therapeutics, equity (E.D., D.J.M., F.L., B.S.). David Walt has a financial interest in Quanterix Corporation, a company that develops an ultra‐sensitive digital immunoassay platform. He is an inventor of the Simoa technology, a founder of the company and also serves on its Board of Directors. Dr. Walt's interests were reviewed and are managed by BWH and Partners Healthcare in accordance with their conflict‐of‐interest policies."

"The authors want to thank Dr. Mohan Karkada, Dr. Hua Wang, David Zhang and Miguel Sobral for helpful discussions and valuable input. This work was supported by the Wyss Institute for Biologically Inspired Engineering."